What is Leerink Partnrs’ Forecast for OKUR Q1 Earnings?

OnKure Therapeutics (NASDAQ:OKUR) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of OnKure Therapeutics in a research note issued on Monday, April 28th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($1.22) per share for the quarter. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($1.35) EPS, Q4 2025 earnings at ($1.22) EPS, FY2026 earnings at ($3.78) EPS and FY2027 earnings at ($4.61) EPS.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Monday, March 10th. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.51).

OKUR has been the topic of a number of other reports. Evercore ISI assumed coverage on OnKure Therapeutics in a report on Wednesday. They issued an “outperform” rating on the stock. HC Wainwright dropped their target price on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Finally, Oppenheimer reduced their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, OnKure Therapeutics currently has a consensus rating of “Buy” and an average price target of $32.33.

OnKure Therapeutics Stock Performance

NASDAQ OKUR opened at $2.50 on Thursday. The stock has a market cap of $33.59 million, a price-to-earnings ratio of -0.20 and a beta of 0.35. OnKure Therapeutics has a 12 month low of $2.42 and a 12 month high of $20.00. The company’s 50 day moving average is $3.88 and its two-hundred day moving average is $8.51.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OKUR. Highbridge Capital Management LLC acquired a new stake in OnKure Therapeutics in the 4th quarter valued at about $3,438,000. Geode Capital Management LLC acquired a new stake in shares of OnKure Therapeutics in the fourth quarter valued at approximately $659,000. Aisling Capital Management LP purchased a new position in OnKure Therapeutics during the fourth quarter worth approximately $762,000. Aldebaran Capital LLC acquired a new position in OnKure Therapeutics during the fourth quarter worth $392,000. Finally, Renaissance Technologies LLC purchased a new stake in OnKure Therapeutics in the 4th quarter valued at $408,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.